Recently, multiple clinical trials (such as NCT02923180 and NCT02475213) have confirmed the antitumor effectiveness and safety of enoblituzumab [53], a humanized Fc-engineered B7-H3-targeting antibody, in patients with localized prostate cancer (PCa), advanced head and neck squamous cell carcinoma, and non-small cell lung cancer (NSCLC) [54,55]. Here, CD276 is linked to posterior cortical atrophy.